宫颈癌患者血清鳞状细胞癌抗原、尿激酶型纤溶酶原激活物受体、CD105、转化生长因子-β水平及临床意义  

Serum levels of squamous cell carcinoma antigen,urokinase-type plasminogen activator receptor,CD105 and transforming growth factor-β in patients with cervical cancer and their clinical significance

作　　者：李静[1] 刘静[2] 张燕[3] LI Jing;LIU Jing;ZHANG Yan(Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,He’nan,China;Department of Ear-Nose-Throat,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,He’nan,China;Department of Clinical Laboratory,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,He’nan,China)

机构地区：[1]郑州大学第一附属医院肿瘤科,郑州4500000 [2]郑州大学第一附属医院耳鼻喉科,郑州4500000 [3]郑州大学第一附属医院检验科,郑州4500000

出　　处：《癌症进展》2021年第13期1367-1370,共4页Oncology Progress

摘　　要：目的探讨宫颈癌患者血清鳞状细胞癌抗原(SCCA)、尿激酶型纤溶酶原激活物受体(u PAR)、CD105、转化生长因子-β(TGF-β)水平及临床意义。方法选取158例宫颈癌患者和50例宫颈上皮内瘤变(CIN)患者,分别作为宫颈癌组和CIN组,检查两组患者的血清SCCA、u PAR、CD105、TGF-β水平,分析血清SCCA、u PAR、CD105、TGF-β水平与宫颈癌患者临床特征的关系。结果宫颈癌组患者的血清SCCA、u PAR、CD105和TGF-β水平均明显高于CIN组,差异均有统计学意义(P﹤0.01)。TNM分期为Ⅲ~Ⅳ期、有淋巴结转移宫颈癌患者的血清SCCA水平分别高于TNM分期为Ⅰ~Ⅱ期、无淋巴结转移的患者(P﹤0.05),低分化宫颈癌患者的血清u PAR水平高于中高分化的患者(P﹤0.05),TNM分期为Ⅲ~Ⅳ期、肿瘤直径≥5 cm、低分化、有淋巴结转移宫颈癌患者的血清CD105水平分别高于TNM分期为Ⅰ~Ⅱ期、肿瘤直径﹤5 cm、中高分化、无淋巴结转移的患者(P﹤0.05),有淋巴结转移宫颈癌患者的血清TGF-β水平高于无淋巴结转移的患者(P﹤0.05)。宫颈癌患者的血清SCCA与TGF-β水平呈正相关(r=0.431,P﹤0.05),血清u PAR与CD105水平呈正相关(r=0.332,P﹤0.05)。治疗1个月后宫颈癌患者的血清SCCA、u PAR、CD105和TGF-β水平均明显低于治疗前(P﹤0.01)。结论宫颈癌患者的血清SCCA、u PAR、CD105和TGF-β水平均明显升高,且其表达水平与患者的临床特征具有一定关系,值得进一步研究。Objective To investigate the serum levels of squamous cell carcinoma antigen(SCCA),urokinase-type plasminogen activator receptor(u PAR),CD105 and transforming growth factor-β(TGF-β)in patients with cervical cancer and their clinical significance.Method 158 cases of cervical cancer patients(cervical cancer group)and 50 cases of cervical intraepithelial neoplasia(CIN)patients(CIN group)were selected,the levels of serum SCCA,u PAR,CD105,TGF-βin the two groups were detected,and the relationship of serum SCCA,u PAR,CD105 and TGF-βwith clinical characteristics of cervical cancer patients was analyzed.Result The levels of serum SCCA,u PAR,CD105 and TGF-βin cervical cancer group were significantly higher than those in CIN group(P<0.01).The serum SCCA levels of patients with TNM stageⅢ-Ⅳand lymph node metastasis were significantly higher than those of patients with TNM stageⅠ-Ⅱand without lymph node metastasis(P<0.05);the serum u PAR level of patients with low differentiation was significantly higher than that of patients with moderate and high differentiation(P<0.05);the serum CD105 levels of patients with TNM stageⅢⅣ,tumor diameter≥5 cm,poor differentiation and lymph node metastasis were significantly higher than those of patients with TNM stageⅠ-Ⅱ,tumor diameter<5 cm,moderate and high differentiation and no lymph node metastasis(P<0.05);the serum TGF-βlevel in patients with lymph node metastasis was significantly higher than that of patients without lymph node metastasis(P<0.05).There was a positive correlation between serum SCCA and TGF-βin patients with cervical cancer(r=0.431,P<0.05),and serum u PAR was positively correlated with CD105(r=0.332,P<0.05).After 1 month of treatment,the serum SCCA,u PAR,CD105 and TGF-βwere significantly lower than those before treatment(P<0.01).Conclu Conclusion The levels of serum SCCA,u PAR,CD105 and TGF-βof patients with cervical cancer are significantly increased and related to the clinical characteristics,which is worthy of further study.

关 键 词：宫颈癌 鳞状细胞癌抗原 尿激酶型纤溶酶原激活物受体 CD105 转化生长因子-Β 临床意义 

分 类 号：R737.33[医药卫生—肿瘤]